These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 14707891

  • 1. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
    Paragh G, Seres I, Harangi M, Balogh Z, Illyés L, Boda J, Szilvássy Z, Kovács P.
    Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
    [Abstract] [Full Text] [Related]

  • 2. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Dec; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects.
    Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F.
    Atherosclerosis; 2002 Jun; 162(2):381-9. PubMed ID: 11996958
    [Abstract] [Full Text] [Related]

  • 6. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
    Tan CE, Chew LS, Tai ES, Chio LF, Lim HS, Loh LM, Shepherd J.
    Atherosclerosis; 2001 Feb 01; 154(2):469-74. PubMed ID: 11166781
    [Abstract] [Full Text] [Related]

  • 7. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar 01; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 8. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.
    Am J Cardiol; 2003 Apr 15; 91(8):956-60. PubMed ID: 12686335
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 15; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H.
    J Cardiovasc Pharmacol; 1996 Apr 15; 27(4):563-70. PubMed ID: 8847874
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS.
    Eur J Clin Pharmacol; 2000 Dec 15; 56(9-10):631-5. PubMed ID: 11214768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D, Bonfiglioli D, Pogliaghi I, Ottomano C, Fasoli A.
    Eur J Clin Pharmacol; 1984 Dec 15; 26(6):741-4. PubMed ID: 6489413
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
    Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC, FIELD study investigators.
    Diabetologia; 2010 Sep 15; 53(9):1846-55. PubMed ID: 20526762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.